Vagotonic Effect of Remifentanil in Reference to Sympathetic or Parasympathetic Predominance of Autonomic Nervous System.

Trial Profile

Vagotonic Effect of Remifentanil in Reference to Sympathetic or Parasympathetic Predominance of Autonomic Nervous System.

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2015

At a glance

  • Drugs Remifentanil (Primary)
  • Indications Intraoperative pain
  • Focus Pharmacodynamics
  • Most Recent Events

    • 07 Oct 2015 Last Checked against ClinicalTrials.gov record.
    • 01 Oct 2015 The time frame for primary end point will be analysed now before and now injection instead of up to 2 years as reported by ClinicalTrials.gov record.
    • 03 Aug 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top